ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "aortitis"

  • Abstract Number: 1865 • ACR Convergence 2021

    Incidence, Prevalence, and Mortality of Chronic Periaortitis: A Population-based Study

    Umar Ghaffar1, Kenneth Warrington2, Stephanie Duong1, Cynthia Crowson3, Michelle Burke1, Boyd Viers1, Aaron Potretzke1, Haraldur Bjarnason1 and Matthew Koster1, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Rochester, Minnesota, 3Mayo Clinic, Eyota, MN

    Background/Purpose: Chronic periaortitis is an inflammatory condition that typically involves the infrarenal portion of the abdominal aorta. To date, no epidemiologic studies have been performed…
  • Abstract Number: 945 • 2019 ACR/ARP Annual Meeting

    Comparison of Clinical Manifestations in IgG4 Related Disease Patients with/without Aortitis/Periaortitis and Periarteritis: A Prospective Cohort Study of 587 Patients with IgG4-RD Disease

    Linyi Peng 1, Wen Zhang 2 and Panpan Zhang1, 1Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China (People's Republic), 2Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China (People's Republic)

    Background/Purpose: We aimed to clarify the clinical features of IgG4-related disease (IgG4-RD) with/without aortitis/periaortitis and periarteritis (PAO/PA), and evaluate the treatment efficacy of patients with…
  • Abstract Number: 1181 • 2019 ACR/ARP Annual Meeting

    Tocilizumab in Aortitis: A Multicenter Study of 79 Patients

    Mónica Calderón-Goercke1, Javier Loricera 2, DIANA PRIETO- PENA 3, Vicente Aldasoro Caceres 4, Santos Castañeda 5, Ignacio Villa 6, Alicia Humbría 7, Clara Moriano 8, Susana Romero-Yuste 9, Javier Narváez 10, Catalina Gómez-Arango 11, Eva Perez Pampín 12, Rafael Melero 13, Marcelino Revenga 14, Noelia Álvarez-Rivas 15, Francisca Sivera 16, María Álvarez del buergo 17, Luisa Marena-Rojas 18, Eva Galindez-Agirregoikoa 19, Beatriz Arca 20, Roser Solans-Laqué 21, Carlos Vazquez 22, Pau Lluch 23, Eva salgado-Pérez 24, Cristina Luna-Gómez 25, F. Javier Toyos-Sáenz De Miera 26, Nagore Fernández-Llanio 27, Antonio García 28, Carmen Larena 29, Lara Sanchez-Bilbao 1, Iñigo Gonzalez-Mazon 3, Natalia Palmou-Fontana 3, Vanesa Calvo-Río 1, Carmen González-Vela 1, Alfonso Corrales 30, María Varela-García 4, Elena Aurrecoechea 6, Raquel Dos Santos 31, Sabela Fernández 20, Jose Luis Hernández 1, Miguel Angel González-Gay 32 and Ricardo Blanco 33, 1Hospital Marqués de Valdecilla, Santander, Cantabria, Spain, 2Rheumatology Department. Hospital Marqués de Valdecilla, Santander, Cantabria, Spain, 3Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, 4Complejo Hospitalario de Navarra, Navarra, Navarra, Spain, 5Rheumatology Department, Hospital Universitario de la Princesa, IIS-Princesa, Madrid, Spain, Madrid, Spain, 6Hospital de Sierrallana, Torrelavega, Cantabria, Spain, 7Hospital de La Princesa, Madrid, Madrid, Spain, 8Complejo Asistencial Universitario de León, León, Castilla y Leon, Spain, 9Complejo Hospitalario Universitario Pontevedra, Pontevedra, Galicia, Spain, 10Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, Barcelona, Catalonia, Spain, 11Hospital Alto Deba, Mondragon, Pais Vasco, Spain, 12Division of Rheumatology, Instituto de Investigación Sanitaria-Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, Santiago de Compostela, Spain, 13Complexo Hospitalario Universitario de Vigo, Vigo, Galicia, Spain, 14Hospital Ramón y Cajal, Madrid, Madrid, Spain, 15Hospital Universitario Lucus Augusti, Lugo, Galicia, Spain, 16Hospital General Universitario de Elda, Elda, Spain, 17Hospital Río Carrión, Palencia, Castilla y Leon, Spain, 18Hospital La Mancha Centro, Alcázar de San Juan, Castilla-La Mancha, Spain, 19Hospital de Basurto, Bilbao, Pais Vasco, Spain, 20Hospital Universitario San Agustín, Avilés, Asturias, Spain, 21Department of Internal Medicine, Hospital Vall d'Hebron, Barcelona, Spain., Barcelona, Catalonia, Spain, 22Hospital Miguel Servet, Zaragoza, Aragon, Spain, 23Hospital Mateu Orfila, Menorca, Islas Baleares, Spain, 24Complejo Hospitalario Universitario de Ourense, Ourense, Galicia, Spain, 25Hospital Universitario Nuestra Señora de la Candelaria, Tenerife, Canarias, Spain, 26Hospital Universitario Virgen Macarena, Sevilla, Andalucia, Spain, 27Hospital Arnau de Vilanova, Lérida, Catalonia, Spain, 28Hospital Virgen de las Nieves, Granada, Andalucia, Spain, 29Hospital Universitario Ramón y Cajal, Madrid, Madrid, Spain, 30Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, Santander, Spain, 31Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Galicia, Spain, 32Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 33Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain

    Background/Purpose: Aortitis can be idiopathic or associated with other conditions. It is frequently refractory to conventional immunosuppressive therapy. Tocilizumab (TCZ), an anti-IL-6 receptor antibody seems…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology